'Resource-limited' PolyMedix prioritises antibiotics over anticoagulants
This article was originally published in Scrip
Executive Summary
PolyMedix announced on 10 May that it stopped enrolling patients in two clinical trials for the anticoagulant reversing agent PMX-60056 due to reductions in blood pressure observed in study participants.